Originally published by our sister publication Specialty Pharmacy Continuum
By SPC Staff
The FDA approved infliximab-dyyb (Zymfentra, Celltrion) for the treatment of inflammatory bowel disease.
The drug is the first subcutaneous formulation of infliximab to gain approval for the maintenance treatment of adults with moderately to severely active ulcerative colitis and Crohn’s disease. Infliximab-dyyb is given following treatment with an infliximab product administered intravenously. It